Tracing specificity of immune landscape remodeling associated with distinct anticancer treatments
Year: 2025
Type: article
Abstract: Immune cells within the tumor microenvironment impact cancer progression, resistance, response to treatments. Despite remarkable outcomes for some cancer patients, immunotherapies remain unsatisfactory for others. Here, we designed an experimental setting using the Alb-R26 Met "inside-out" mouse model, faithfully recapitulating molecular features of liver cancer patients, to explore the effects of distinct anticancer targeted therapies on the tumor immune landscape. Using two treatments in clinical trials for different cancer types, Decitabine and MEK+BCL-XL blockage, we show their capability to trigger tumor regression in Alb-R26 Met mice and to superimpose distinct profiles of immune cell types and immune-checkpoints, impacting immunotherapy response. A machine learning approach processing tumor imaging and immune profile data identified a putative signature predicting tumor treatment response in mice and patients. Outcomes exemplify how the tumor immune microenvironment is differentially reshaped by distinct anticancer agents and highlight the importance of measuring its modulation during treatment to optimize oncotherapy and immunotherapy combinations.
Source: iScience
Authors: Floriane Cannet, Célia Sequera, Paula Michea Veloso, Abdessamad El Kaoutari, Melissa Methia, Sylvie Richelme, Muge Kaya, Afef Cherni, Mathieu Dupont, Jean-Paul Borg, Christian Morel, Yannick Boursier, Flavio Maina
Institutions: Centre National de la Recherche Scientifique, Inserm, Aix-Marseille Université, Centre de physique des particules de Marseille, Institut de Biologie du Développement Marseille, Institut National de Physique Nucléaire et de Physique des Particules, Centre de Recherche en Cancérologie de Marseille, Institut Paoli-Calmettes, Institut Universitaire de France
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,240
Funders: Association pour la Recherche sur le Cancer, Agence Nationale de la Recherche, Institut National de la Santé et de la Recherche Médicale, Fondation pour la Recherche Médicale, Fondation de France, Centre National de la Recherche Scientifique, Institut National Du Cancer, Association Française pour l'Etude du Foie, Conseil Régional Provence-Alpes-Côte d'Azur, Canceropôle Provence-Alpes-Côte d’Azur, Groupement des Entreprises Françaises dans la lutte contre le Cancer, Société d'Accélération du Transfert de Technologies
OpenAlex ID: W4407793853